about
GPR40 agonists for the treatment of type 2 diabetes: life after 'TAKing' a hit.Fasiglifam for glycaemic control in people with type 2 diabetes: A phase III, placebo-controlled study.Free fatty acid receptor agonists for the treatment of type 2 diabetes: drugs in preclinical to phase II clinical development.Free Fatty Acid Receptor 1 (FFAR1) as an Emerging Therapeutic Target for Type 2 Diabetes Mellitus: Recent Progress and Prevailing Challenges.Identification of an Orally Efficacious GPR40/FFAR1 Receptor Agonist.Structural basis for the agonist action at free fatty acid receptor 1 (FFA1R or GPR40).
P2860
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Optimization of GPR40 Agonists for Type 2 Diabetes.
@en
Optimization of GPR40 Agonists for Type 2 Diabetes.
@nl
type
label
Optimization of GPR40 Agonists for Type 2 Diabetes.
@en
Optimization of GPR40 Agonists for Type 2 Diabetes.
@nl
prefLabel
Optimization of GPR40 Agonists for Type 2 Diabetes.
@en
Optimization of GPR40 Agonists for Type 2 Diabetes.
@nl
P2093
P2860
P356
P1476
Optimization of GPR40 Agonists for Type 2 Diabetes
@en
P2093
Daniel C-H Lin
Gayathri Swaminath
George R Tonn
Jane Zhang
Jiwen Jim Liu
Jonathan B Houze
Julio C Medina
Liusheng Zhu
Mike Schmitt
P2860
P304
P356
10.1021/ML400501X
P50
P577
2014-02-06T00:00:00Z